abstract |
The invention relates to cyclobutane and methylcyclobutane derivatives, as well as their salts, compositions and methods of use, which are Janus kinase (JAK) inhibitors useful in the treatment of JAK-associated diseases, including, for example, inflammatory and autoimmune disorders, as well as a malignant tumor and myeloproliferative disorders. |